BUND FINANCE › Stocks › MRNA
Moderna, Inc. (MRNA)
NASDAQ · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed
Key stats
Quick technical read
- Price is -3.72% below its 50-day average.
- It is +100.62% above its 200-day average (long-term uptrend).
- It sits at 68% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | US$17.7B | US$18.9B | US$6.8B | US$3.2B | US$1.9B |
| Net income | US$12.2B | US$8.4B | −US$4.7B | −US$3.6B | −US$2.8B |
| EPS (diluted) | 28.29 | 20.10 | -12.34 | -9.27 | -7.26 |
| Gross margin | 85.2% | 71.3% | 31.5% | 54.2% | 55.4% |
| Operating margin | 75.0% | 49.9% | -61.9% | -123.3% | -158.1% |
| Net margin | 68.8% | 44.3% | -68.8% | -111.3% | -145.2% |
| Free cash flow | US$13.3B | US$4.6B | −US$3.8B | −US$4.1B | −US$2.1B |
| Total debt | US$916.0M | US$1.2B | US$1.2B | US$747.0M | US$1.3B |
| Cash | US$6.8B | US$3.2B | US$2.9B | US$1.9B | US$2.6B |
Compound annual growth: revenue -42.5% · net income — (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | — | 8.4x | 27.1x |
| EV / EBITDA | — | 7.0x | 16.5x |
| Operating margin | -116.0% | — | 3.6% |
| Net margin | -110.5% | — | -0.0% |
| Debt / equity | 0.97 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.
About Moderna, Inc.
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr vi…
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice